UCDCC#272: A Phase I/II Study of Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Standard-of-Care PD-1/PD-L1 Checkpoint Blockade

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Apr 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Interleukin-2 (Primary) ; Pembrolizumab (Primary)
Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Squamous cell cancer
Focus Therapeutic Use

06 Apr 2023 Planned End Date changed from 1 Jul 2023 to 1 Dec 2023.
06 Apr 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
06 Apr 2023 Status changed from active, no longer recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com